Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CBM NASDAQ:EIDX NASDAQ:FTSV NASDAQ:HRTX NASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMCambrex$59.99$59.99$33.80▼$60.29$2.02B2.14218,726 shsN/AEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AHRTXHeron Therapeutics$1.32+1.2%$1.33$1.04▼$2.68$241.07M1.251.66 million shs654,773 shsXNCRXencor$12.59-9.8%$9.31$6.92▼$27.24$907.12M0.96825,592 shs2.30 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMCambrex0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%HRTXHeron Therapeutics+1.56%-2.99%+3.17%-36.27%-29.35%XNCRXencor+7.14%+18.41%+62.33%+65.40%-34.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBMCambrex$59.99$59.99$33.80▼$60.29$2.02B2.14218,726 shsN/AEIDXEidos Therapeutics$122.21$123.21$28.39▼$132.54$4.75B-0.16128,113 shsN/AFTSVForty Seven$95.51$95.51$5.53▼$95.51$4.60B0.41.61 million shsN/AHRTXHeron Therapeutics$1.32+1.2%$1.33$1.04▼$2.68$241.07M1.251.66 million shs654,773 shsXNCRXencor$12.59-9.8%$9.31$6.92▼$27.24$907.12M0.96825,592 shs2.30 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBMCambrex0.00%0.00%0.00%0.00%0.00%EIDXEidos Therapeutics0.00%0.00%0.00%0.00%0.00%FTSVForty Seven0.00%0.00%0.00%0.00%0.00%HRTXHeron Therapeutics+1.56%-2.99%+3.17%-36.27%-29.35%XNCRXencor+7.14%+18.41%+62.33%+65.40%-34.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBMCambrex 0.00N/AN/AN/AEIDXEidos Therapeutics 0.00N/AN/AN/AFTSVForty Seven 0.00N/AN/AN/AHRTXHeron Therapeutics 2.25Hold$4.50242.21% UpsideXNCRXencor 2.64Moderate Buy$24.2292.39% UpsideCurrent Analyst Ratings BreakdownLatest FTSV, CBM, HRTX, EIDX, and XNCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/7/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/6/2025XNCRXencorCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$40.009/27/2025HRTXHeron TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025XNCRXencorWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/17/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageUnderweight$6.009/16/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell9/3/2025XNCRXencorBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$23.00 ➝ $12.009/2/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$26.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBMCambrex$532.09M3.80$3.91 per share15.36$19.48 per share3.08EIDXEidos Therapeutics$26.69M177.99N/AN/A$4.57 per share26.74FTSVForty Seven$15.68M293.33N/AN/A$7.52 per share12.70HRTXHeron Therapeutics$144.29M1.67N/AN/A($0.22) per share-5.98XNCRXencor$110.49M8.13N/AN/A$9.63 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBMCambrex$92.41M$2.7721.66∞N/A5.96%5.38%2.50%N/AEIDXEidos Therapeutics-$37.83M-$1.03N/AN/AN/AN/A-65.21%-53.04%N/AFTSVForty Seven-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/AHRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)XNCRXencor-$232.62M-$2.40N/AN/AN/A-121.52%-25.75%-18.19%11/5/2025 (Estimated)Latest FTSV, CBM, HRTX, EIDX, and XNCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025HRTXHeron Therapeutics-$0.02N/AN/AN/A$39.03 millionN/A11/5/2025Q3 2025XNCRXencor-$0.72N/AN/AN/A$29.73 millionN/A8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/6/2025Q2 2025XNCRXencor-$0.78-$0.41+$0.37-$0.41$22.59 million$43.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBMCambrexN/AN/AN/AN/AN/AEIDXEidos TherapeuticsN/AN/AN/AN/AN/AFTSVForty SevenN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBMCambrex0.762.371.70EIDXEidos Therapeutics0.1411.1011.10FTSVForty SevenN/A14.8114.81HRTXHeron TherapeuticsN/A0.820.53XNCRXencorN/A5.345.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBMCambrex90.96%EIDXEidos Therapeutics31.40%FTSVForty Seven71.77%HRTXHeron Therapeutics80.01%XNCRXencorN/AInsider OwnershipCompanyInsider OwnershipCBMCambrex1.41%EIDXEidos Therapeutics70.10%FTSVForty Seven37.40%HRTXHeron Therapeutics5.86%XNCRXencor5.23%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBMCambrex1,73233.72 millionN/AOptionableEIDXEidos Therapeutics7038.87 millionN/ANot OptionableFTSVForty Seven5748.16 millionN/ANot OptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableXNCRXencor28071.32 million67.59 millionOptionableFTSV, CBM, HRTX, EIDX, and XNCR HeadlinesRecent News About These CompaniesXencor (NASDAQ:XNCR) Trading Down 13.3% - Should You Sell?2 hours ago | marketbeat.comXencor (NASDAQ:XNCR) Receives "Sell (D-)" Rating from Weiss Ratings3 hours ago | marketbeat.comXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics4 hours ago | businesswire.comXencor Sees RS Rating Rise To 73October 13 at 12:37 AM | msn.comAnalysts Offer Predictions for Xencor FY2025 EarningsOctober 12 at 2:11 AM | americanbankingnews.comEquities Analysts Issue Forecasts for Xencor FY2025 EarningsOctober 11 at 6:56 AM | marketbeat.comXencor (NASDAQ:XNCR) Upgraded at Cantor FitzgeraldOctober 11 at 3:39 AM | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 11 at 2:45 AM | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Moderate Buy" by AnalystsOctober 11 at 2:43 AM | marketbeat.comXencor (NASDAQ:XNCR) Raised to Strong-Buy at Cantor FitzgeraldOctober 10, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Xencor (NASDAQ:XNCR)October 8, 2025 | americanbankingnews.comCantor Fitzgerald Forecasts Xencor FY2025 EarningsOctober 7, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Given "Overweight" Rating at Cantor FitzgeraldOctober 6, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading 6.2% Higher - Should You Buy?September 26, 2025 | marketbeat.comXencor: Bispecific Antibody Program Takes Shape With Q4 Data ReleaseSeptember 19, 2025 | seekingalpha.comXencor (XNCR) Receives a Sell from Roth MKMSeptember 19, 2025 | theglobeandmail.comXencor (NASDAQ:XNCR) Upgraded to "Strong Sell" at BarclaysSeptember 19, 2025 | marketbeat.comXencor (NASDAQ:XNCR) Trading Up 5.4% - Time to Buy?September 18, 2025 | marketbeat.comStrength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength?September 18, 2025 | zacks.comXencor (NASDAQ:XNCR) Given "Underweight" Rating at BarclaysSeptember 18, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTSV, CBM, HRTX, EIDX, and XNCR Company DescriptionsCambrex NYSE:CBMCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.Eidos Therapeutics NASDAQ:EIDXEidos Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) or amyloidosis (ATTR). It is developing AG10, which is in phase 3 clinical trial, is an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. The company was founded in 2013 and is headquartered in San Francisco, California. Eidos Therapeutics, Inc. is a subsidiary of BridgeBio Pharma, Inc.Forty Seven NASDAQ:FTSVForty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.Heron Therapeutics NASDAQ:HRTX$1.32 +0.02 (+1.15%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Xencor NASDAQ:XNCR$12.59 -1.37 (-9.81%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
